Genmab A/SGMABNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +37.69% | +18.57% | +652.47% | -81.55% | +4.38% |
| Gross Profit Growth | +34.09% | +16.84% | +632.43% | -81.70% | +1.71% |
| EBITDA Growth | +137.40% | -0.38% | +776.23% | -77.18% | -34.43% |
| Operating Income Growth | +29.34% | +62.07% | +866.66% | -78.16% | -28.51% |
| Net Income Growth | +500.78% | +1.56% | +948.89% | -68.33% | -94.88% |
| EPS Growth | +511.22% | -84.73% | +58.99% | -66.67% | -94.66% |
| EPS Diluted Growth | +517.53% | -84.65% | +57.60% | -66.67% | -95.16% |
| Weighted Average Shares Growth | -1.76% | -2.42% | -4.81% | -5.07% | -3.95% |
| Weighted Average Shares Diluted Growth | -2.48% | -2.63% | -4.46% | -4.33% | +4.84% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -80.48% | +790.41% | +79.40% | -73.64% | +486.39% |
| Free Cash Flow Growth | -81.34% | +712.17% | +53.27% | -73.10% | +511.60% |
| Receivables Growth | +35.25% | +35.16% | +2.53% | -83.42% | +9.48% |
| Inventory Growth | +8.77% | -22.28% | +128.84% | -80.28% | +84.61% |
| Asset Growth | +29.82% | +11.68% | +6.07% | -82.30% | +78.69% |
| Book Value per Share Growth | +18.17% | +5.95% | +13.97% | -81.02% | +5.49% |
| Debt Growth | +33.64% | -7.14% | -7.96% | -85.61% | +3335.93% |
| R&D Expense Growth | +36.76% | +7.16% | +538.97% | -84.36% | +25.46% |
| SG&A Expenses Growth | +33.73% | +0.80% | +607.39% | -82.89% | +5.82% |